NHS Halts Cross-Sex Hormones for Under 18s in England
NHS England suspends gender-affirming cross-sex hormone prescriptions for under-18s, launching a 90-day consultation on permanently removing the treatment.
By James Liu
2 articles tagged "gender dysphoria"
NHS England suspends gender-affirming cross-sex hormone prescriptions for under-18s, launching a 90-day consultation on permanently removing the treatment.
Recent regulatory actions surrounding the UK's Pathways clinical trial examining puberty suppression therapy highlight critical tensions between scientific objectivity and institutional oversight in pediatric gender dysphoria research. The excusal of a key regulatory official raises important questions about research governance and evidence generation in this contested clinical domain.